ReviewCurrent neuropharmacology2017
The Pharmacology of Spinal Opioids and Ziconotide for the Treatment of Non-Cancer Pain.
Review in Current neuropharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 39 citations in OpenAlex.
- Can Ziconotide Be Used to Replace Opioids? Exploratory Clinical Experience in 5 Patients Treated in the Pain Unit.Journal of pain research · 2025Article
- A Benefit/Risk Assessment of Intrathecal Ziconotide in Chronic Pain: A Narrative Review.Journal of clinical medicine · 2024Review
- A Systematic Guideline by the ASPN Workgroup on the Evidence, Education, and Treatment Algorithm for Painful Diabetic Neuropathy: SWEET.Journal of pain research · 2024Review
- Antimicrobial and anticarcinogenic activity of bioactive peptides derived from abalone viscera (Haliotis fulgens and Haliotis corrugata).Scientific reports · 2023Article
- Brief History of Opioids in Perioperative and Periprocedural Medicine to Inform the Future.Ochsner journal · 2023Review
- New opportunities and challenges of natural products research: When target identification meets single-cell multiomics.Acta pharmaceutica Sinica. B · 2022Review
- The Options for Neuraxial Drug Administration.CNS drugs · 2022Review
- Analgesic effect of recombinant GABAergic precursors releasing ω-conotoxin MVIIA in a model of peripheral nerve injury in rats.Molecular pain · 2022Article
- Therapeutic peptides: current applications and future directions.Signal transduction and targeted therapy · 2022Review
- Suppression of host nocifensive behavior by parasitoid wasp venom.Frontiers in physiology · 2022Article
- [What became of Prialt®? : Observational study on the use of ziconotide in the treatment of chronic pain].Schmerz (Berlin, Germany) · 2021Observational
- Intrathecal pain management with ziconotide: Time for consensus?Brain and behavior · 2021Article
- Analgesic and side effects of intravenous recombinant Phα1β.The journal of venomous animals and toxins including tropical diseases · 2020Article
- Marine Ligands of the Pregnane X Receptor (PXR): An Overview.Marine drugs · 2019Review
- Intrathecal Therapy for Chronic Pain: A Review of Morphine and Ziconotide as Firstline Options.Pain medicine (Malden, Mass.) · 2019Review
- Cancer- and Non-cancer Related Chronic Pain: From the Physiopathological Basics to Management.Open medicine (Warsaw, Poland) · 2019Article
- Editorial (Thematic Selection: Spinal Neuropharmacological Agents for the Management of Pain).Current neuropharmacology · 2017Article
- Comparison of intrathecal bupivacaine-fentanyl and bupivacaine-butorphanol combinations for joint replacement surgeries.Journal of anaesthesiology, clinical pharmacologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIntrathecal drug delivery has undergone a revitalization following a better understanding of this delivery route and its pharmacokinetics. Driven by patient safety and outcomes, clinicians are motivated to rethink the traditional spinal infusion pump patient selection criteria and indications. We review the current understanding of the pharmacology of commonly employed intrathecal agents and the clinical relevance.
methodsSearch strategies for data acquisition included Medline database, PubMed, Google scholar, along with international and national professional meeting content, with key words including pharmacology of opioids, intrathecal therapy, ziconotide, pharmacokinetics, and intrathecal drug delivery. The search results were limited to the English language.
resultsOver 300 papers were identified. The literature was condensed and digested to evaluate the most commonly used medications in practice, sto serve as a foundation for review. We review on-label medications: ziconotide and morphine, and off label medications including fentanyl, sufentail, and hydromorphine.
conclusionIntrathecal therapy has level-one evidence for use for malignant pain and nonmalignant pain, with continued cost savings and improved safety. To most effectively serve our patients, a clear appreciation for the pharmacology of these commonly employed medication is paramount.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.